^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EBV-specific anti-PD1 TCR-T cells

    i
    Other names: EBV-specific anti-PD1 TCR-T cells, EBV-specific TCR-T cell with anti-PD1 auto-secreted element
    Associations

    News

    Trials
    Company:
    TCRCure
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    26d
    EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Xinqiao Hospital of Chongqing | Suspended --> Recruiting
    Enrollment open
    |
    IL2 (Interleukin 2)
    |
    EBV-specific anti-PD1 TCR-T cells
    26d
    EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Xinqiao Hospital of Chongqing | Suspended --> Recruiting
    Enrollment open • Metastases
    |
    EBV-specific anti-PD1 TCR-T cells
    2ms
    EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov)
    P1/2, N=18, Suspended, Xinqiao Hospital of Chongqing | Trial completion date: Jan 2024 --> Dec 2024 | Recruiting --> Suspended | Trial primary completion date: Jan 2024 --> Dec 2024
    Trial completion date • Trial suspension • Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    EBV-specific anti-PD1 TCR-T cells
    2ms
    EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P1/2, N=20, Suspended, Xinqiao Hospital of Chongqing | Trial completion date: Aug 2023 --> Dec 2024 | Recruiting --> Suspended | Trial primary completion date: Aug 2023 --> Dec 2024
    Trial completion date • Trial suspension • Trial primary completion date • Metastases
    |
    EBV-specific anti-PD1 TCR-T cells
    almost2years
    EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Xinqiao Hospital of Chongqing | Trial completion date: Feb 2022 --> Jan 2024 | Trial primary completion date: Feb 2022 --> Jan 2024
    Trial completion date • Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    EBV-specific anti-PD1 TCR-T cells